Effect of Colchicine vs Standard Care on Cardiac and Inflammatory Biomarkers and Clinical Outcomes in Patients Hospitalized with Coronavirus Disease 2019: The GRECCO-19 Randomized Clinical Trial

JAMA Network Open

Volumn 3, Issue 6, 2020, Pages

  Deftereos, Spyridon G ^a   Giannopoulos, Georgios ^b   Vrachatis, Dimitrios A ^c   Siasos, Gerasimos D ^a   Giotaki, Sotiria G ^a   Gargalianos, Panagiotis ^d   Metallidis, Simeon ^e   Sianos, George ^e   Baltagiannis, Stefanos ^f   Panagopoulos, Periklis ^g   Dolianitis, Konstantinos ^h   Randou, Efthalia ⁱ   Syrigos, Konstantinos ^a   Kotanidou, Anastasia ^a   Koulouris, Nikolaos G ^a   Milionis, Haralampos ^j   Sipsas, Nikolaos ^k   Gogos, Charalampos ^l   Tsoukalas, George ^m   Olympios, Christoforos D ⁿ   Tsagalou, Eleftheria ^o   Migdalis, Ilias ^p   Gerakari, Styliani ^m   Angelidis, Christos ^a   Alexopoulos, Dimitrios ^a   Davlouros, Pericles ^q   Hahalis, George ^q   Kanonidis, Ioannis ^e   Katritsis, Demosthenes ^r   Kolettis, Theofilos ^j   Manolis, Antonios S ^a   Michalis, Lampros ^j   Naka, Katerina K ^j   Pyrgakis, Vlasios N ^b   Toutouzas, Konstantinos P ^a   Triposkiadis, Filippos ^s   Tsioufis, Konstantinos ^a   Vavouranakis, Emmanouil ^a   Martinèz Dolz, Luis ^t   Reimers, Bernhard ^c   Stefanini, Giulio G ^c   Cleman, Michael ^u   Goudevenos, John ^j   Tsiodras, Sotirios ^a   Tousoulis, Dimitrios ^a   Iliodromitis, Efstathios ^a   Mehran, Roxana ^v   Dangas, George ^v   Stefanadis, Christodoulos ^a,d   more..

^a UNIVERSITY OF ATHENS   (Greece)

^b KAT HOSPITAL   (Greece)

^c HUMANITAS CLINICAL AND RESEARCH CENTER   (Italy)

^d ATHENS MEDICAL CENTER   (Greece)

^e ARISTOTLE UNIVERSITY OF THESSALONIKI   (Greece)

^f General Hospital of Kastoria   (Greece)

^g DEMOCRITUS UNIVERSITY OF THRACE   (Greece)

^h Mpodosakio General Hospital of Ptolemaida   (Greece)

ⁱ General Hospital of Kozani   (Greece)

^j UNIVERSITY HOSPITAL OF IOANNINA   (Greece)

^k LAIKO GENERAL HOSPITAL   (Greece)

^l UNIVERSITY HOSPITAL OF PATRAS   (Greece)

^m IASO GENERAL HOSPITAL   (Greece)

ⁿ General Hospital of Elefsina Thriasio   (Greece)

^o ALEXANDRA HOSPITAL   (Greece)

^p NIMTS HOSPITAL   (Greece)

^q UNIVERSITY OF PATRAS   (Greece)

^r HYGEIA HOSPITAL   (Greece)

^s GENERAL HOSPITAL OF LARISSA   (Greece)

^t HOSPITAL UNIVERSITARIO LA FE   (Spain)

^u YALE UNIVERSITY SCHOOL OF MEDICINE   (United States)

^v MOUNT SINAI SCHOOL OF MEDICINE   (United States)

more..

Author keywords

[No Author keywords available]

Indexed keywords

AZITHROMYCIN; C REACTIVE PROTEIN; CHLOROQUINE; COLCHICINE; D DIMER; HYDROXYCHLOROQUINE; LIVER ENZYME; TROPONIN; FIBRIN DEGRADATION PRODUCT; FIBRIN FRAGMENT D; TUBULIN MODULATOR;

ABDOMINAL PAIN; ACUTE KIDNEY FAILURE; ADULT; AGED; ALL CAUSE MORTALITY; ALLERGIC REACTION; ARTICLE; BIOCHEMICAL COMPOSITION; CLINICAL OUTCOME; COMPARATIVE STUDY; CONTROLLED STUDY; CORONAVIRUS DISEASE 2019; DEMOGRAPHY; DIARRHEA; DISEASE SEVERITY; DRUG EFFECT; DRUG WITHDRAWAL; EPISTAXIS; EVENT FREE SURVIVAL; FEMALE; GREECE; HEADACHE; HOSPITAL DISCHARGE; HOSPITAL PATIENT; HUMAN; LOADING DRUG DOSE; MAINTENANCE THERAPY; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY; MUSCLE SPASM; NAUSEA; OPEN STUDY; PANCYTOPENIA; PRIORITY JOURNAL; PROSPECTIVE STUDY; RANDOMIZED CONTROLLED TRIAL; RASH; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; SINGLE DRUG DOSE; THORAX PAIN; THROMBOCYTOPENIA; THROMBOPHLEBITIS; VOMITING; ARTIFICIAL VENTILATION; BETACORONAVIRUS; CAUSE OF DEATH; CORONAVIRUS INFECTION; DISEASE EXACERBATION; HOSPITALIZATION; INFLAMMATION; KAPLAN MEIER METHOD; METABOLISM; MIDDLE AGED; MORTALITY; PANDEMIC; TIME FACTOR; TREATMENT OUTCOME; VERY ELDERLY; VIRUS PNEUMONIA;

AGED; AGED, 80 AND OVER; BETACORONAVIRUS; C-REACTIVE PROTEIN; CAUSE OF DEATH; COLCHICINE; CORONAVIRUS INFECTIONS; DIARRHEA; DISEASE PROGRESSION; FEMALE; FIBRIN FIBRINOGEN DEGRADATION PRODUCTS; GREECE; HOSPITALIZATION; HUMANS; INFLAMMATION; KAPLAN-MEIER ESTIMATE; MALE; MIDDLE AGED; MORTALITY; PANDEMICS; PNEUMONIA, VIRAL; RESPIRATION, ARTIFICIAL; TIME FACTORS; TREATMENT OUTCOME; TROPONIN; TUBULIN MODULATORS;

EID: 85087033955     PISSN: None     EISSN: 25743805     Source Type: Journal    
DOI: 10.1001/jamanetworkopen.2020.13136     Document Type: Article

References (34)

1. Wu C, Chen X, Cai Y, Risk factors associated with acute respiratory distress syndrome and death in patients with coronavirus disease 2019 pneumonia in Wuhan, China. JAMA Intern Med. Published online March 13, 2020. doi: 10.1001/jamainternmed.2020.0994 32167524
2. Deftereos S, Giannopoulos G, Papoutsidakis N, Colchicine and the heart: pushing the envelope. J Am Coll Cardiol. 2013; 62 (20): 1817-1825. doi: 10.1016/j.jacc.2013.08.726 24036026
3. Leung YY, Yao Hui LL, Kraus VB. Colchicine-update on mechanisms of action and therapeutic uses. Semin Arthritis Rheum. 2015; 45 (3): 341-350. doi: 10.1016/j.semarthrit.2015.06.013 26228647
4. US National Library of Medicine. Colchicine Coronavirus SARS-CoV2 Trial (COLCORONA) (COVID-19). Accessed June 4, 2020. https://clinicaltrials.gov/ct2/show/NCT04322682
5. Deftereos S, Giannopoulos G, Vrachatis DA, Colchicine as a potent anti-inflammatory treatment in COVID-19: can we teach an old dog new tricks? Eur Hear J Cardiovasc Pharmacother. Published online April 27, 2020. doi: 10.1093/ehjcvp/pvaa033
6. Deftereos SG, Siasos G, Giannopoulos G, The Greek Study in the Effects of Colchicine in COVID-19 Complications Prevention (GRECCO-19 study): rationale and study design. Hellenic J Cardiol. Published online April 3, 2020. doi: 10.1016/j.hjc.2020.03.002 32251729
7. National Public Health Organization. Coronavirus disease (COVID-19). Accessed June 3, 2020. https://eody.gov.gr/en
8. Schulz KF, Altman DG, Moher D; CONSORT Group. CONSORT 2010 statement: updated guidelines for reporting parallel group randomised trials. BMC Med. 2010; 8: 18. doi: 10.1186/1741-7015-8-18 20334633
9. World Health Organization. R&D blueprint and COVID-19. Accessed March 25, 2020. https://www.who.int/blueprint/priority-diseases/key-action/novel-coronavirus/en/
10. Cao B, Wang Y, Wen D, A trial of lopinavir-ritonavir in adults hospitalized with severe COVID-19. N Engl J Med. 2020; 382 (19): 1787-1799. doi: 10.1056/NEJMoa2001282 32187464
11. Demirel A, Celkan T, Kasapcopur O, Is familial Mediterranean fever a thrombotic disease or not? Eur J Pediatr. 2008; 167 (3): 279-285. doi: 10.1007/s00431-007-0475-2 17436016
12. Angelidis C, Kotsialou Z, Kossyvakis C, Colchicine pharmacokinetics and mechanism of action. Curr Pharm Des. 2018; 24 (6): 659-663. doi: 10.2174/1381612824666180123110042 29359661
13. Bikdeli B, Madhavan MV, Jimenez D, COVID-19 and thrombotic or thromboembolic disease: implications for prevention, antithrombotic therapy, and follow-up. J Am Coll Cardiol. Published April 15, 2020. doi: 10.1016/j.jacc.2020.04.031 32311448
14. Zhou F, Yu T, Du R, Clinical course and risk factors for mortality of adult inpatients with COVID-19 in Wuhan, China: a retrospective cohort study. Lancet. 2020; 395 (10229): 1054-1062. doi: 10.1016/S0140-6736(20)30566-3 32171076
15. Gupta N, Zhao Y-Y, Evans CE. The stimulation of thrombosis by hypoxia. Thromb Res. 2019; 181: 77-83. doi: 10.1016/j.thromres.2019.07.013 31376606
16. Tardif JC, Kouz S, Waters DD, Efficacy and safety of low-dose colchicine after myocardial infarction. N Engl J Med. 2019; 381 (26): 2497-2505. doi: 10.1056/NEJMoa1912388 31733140
17. Deftereos S, Giannopoulos G, Angelidis C, Anti-inflammatory treatment with colchicine in acute myocardial infarction: a pilot study. Circulation. 2015; 132 (15): 1395-1403. doi: 10.1161/CIRCULATIONAHA.115.017611 26265659
18. Shi S, Qin M, Shen B, Association of cardiac injury with mortality in hospitalized patients with COVID-19 in Wuhan, China. JAMA Cardiol. Published March 25, 2020. doi: 10.1001/jamacardio.2020.0950 32211816
19. Shah B, Pillinger M, Zhong H, Effects of acute colchicine administration prior to percutaneous coronary intervention: COLCHICINE-PCI randomized trial. Circ Cardiovasc Interv. 2020; 13 (4): e008717. doi: 10.1161/CIRCINTERVENTIONS.119.008717 32295417
20. Garcia S, Albaghdadi MS, Meraj PM, Reduction in ST-segment elevation cardiac catheterization laboratory activations in the United States during COVID-19 pandemic. J Am Coll Cardiol. 2020;(April): S0735-1097(20)34913-5. doi: 10.1016/j.jacc.2020.04.011 32283124
21. Chen L, Li X, Chen M, Feng Y, Xiong C. The ACE2 expression in human heart indicates new potential mechanism of heart injury among patients infected with SARS-CoV-2. Cardiovasc Res. 2020; 116 (6): 1097-1100. doi: 10.1093/cvr/cvaa078 32227090
22. Walls AC, Park Y-J, Tortorici MA, Wall A, McGuire AT, Veesler D. Structure, function, and antigenicity of the SARS-CoV-2 spike glycoprotein. Cell. 2020; 181 (2): 281-292.e6. doi: 10.1016/j.cell.2020.02.058 32155444
23. Castaño-Rodriguez C, Honrubia JM, Gutiérrez-Álvarez J, Role of severe acute respiratory syndrome coronavirus viroporins E, 3a, and 8a in replication and pathogenesis. mBio. 2018; 9 (3): e02325-17. doi: 10.1128/mBio.02325-17 29789363
24. Kaksonen M, Roux A. Mechanisms of clathrin-mediated endocytosis. Nat Rev Mol Cell Biol. 2018; 19 (5): 313-326. doi: 10.1038/nrm.2017.132 29410531
25. Stebbing J, Phelan A, Griffin I, COVID-19: combining antiviral and anti-inflammatory treatments. Lancet Infect Dis. 2020; 20 (4): 400-402. doi: 10.1016/S1473-3099(20)30132-8 32113509
26. Shi C-S, Nabar NR, Huang N-N, Kehrl JH. SARS-coronavirus open reading frame-8b triggers intracellular stress pathways and activates NLRP3 inflammasomes. Cell Death Discov. 2019; 5 (1): 101. doi: 10.1038/s41420-019-0181-7 31231549
27. Siu K-L, Yuen K-S, Castaño-Rodriguez C, Severe acute respiratory syndrome coronavirus ORF3a protein activates the NLRP3 inflammasome by promoting TRAF3-dependent ubiquitination of ASC. FASEB J. 2019; 33 (8): 8865-8877. doi: 10.1096/fj.201802418R 31034780
28. Chen I-Y, Moriyama M, Chang M-F, Ichinohe T. Severe acute respiratory syndrome coronavirus viroporin 3a activates the NLRP3 Inflammasome. Front Microbiol. 2019; 10 (JAN): 50. doi: 10.3389/fmicb.2019.00050 30761102
29. Grailer JJ, Canning BA, Kalbitz M, Critical role for the NLRP3 inflammasome during acute lung injury. J Immunol. 2014; 192 (12): 5974-5983. doi: 10.4049/jimmunol.1400368 24795455
30. Li D, Ren W, Jiang Z, Zhu L. Regulation of the NLRP3 inflammasome and macrophage pyroptosis by the p38 MAPK signaling pathway in a mouse model of acute lung injury. Mol Med Rep. 2018; 18 (5): 4399-4409. doi: 10.3892/mmr.2018.9427 30152849
31. Jones HD, Crother TR, Gonzalez-Villalobos RA, The NLRP3 inflammasome is required for the development of hypoxemia in LPS/mechanical ventilation acute lung injury. Am J Respir Cell Mol Biol. 2014; 50 (2): 270-280. doi: 10.1165/rcmb.2013-0087OC 24007300
32. Dolinay T, Kim YS, Howrylak J, Inflammasome-regulated cytokines are critical mediators of acute lung injury. Am J Respir Crit Care Med. 2012; 185 (11): 1225-1234. doi: 10.1164/rccm.201201-0003OC 22461369
33. Marques-da-Silva C, Chaves MM, Castro NG, Coutinho-Silva R, Guimaraes MZP. Colchicine inhibits cationic dye uptake induced by ATP in P2X2 and P2X7 receptor-expressing cells: implications for its therapeutic action. Br J Pharmacol. 2011; 163 (5): 912-926. doi: 10.1111/j.1476-5381.2011.01254.x 21306580
34. Misawa T, Takahama M, Kozaki T, Microtubule-driven spatial arrangement of mitochondria promotes activation of the NLRP3 inflammasome. Nat Immunol. 2013; 14 (5): 454-460. doi: 10.1038/ni.2550 23502856